Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalation of Irinotecan and Cisplatin in ES-SCLC
NCT02171325Phase 2Unknown
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Jun 2014
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan in small cell lung cancer (SCLC), sponsored by Guangdong Association of Clinical Trials. Status: unknown.
02
Drugs
irinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02171325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171325.